Search

Your search keyword '"Vasile, E."' showing total 935 results
Start Over Author "Vasile, E."
935 results on '"Vasile, E."'

8. Bone metastases in biliary cancers: A multicenter retrospective survey

Author

Santini, D, Brandi, G, Aprile, G, Russano, M, Cereda, S, Leone, F, Lonardi, S, Fornaro, L, Scartozzi, M, Silvestris, N, Barni, S, Pantano, F, Vincenzi, B, Palloni, A, Frega, G, Casagrande, M, Ferrari, L, Dadduzio, V, Intini, R, Filippi, R, Vasile, E, Vivaldi, C, Faloppi, L, Brunetti, O, Reni, M, Aglietta, M, and Tonini, G

Published
2018
Full Text
View/download PDF

20. 1307P Real-world impact of olaparib use in advanced pancreatic cancer (PC) patients (pts) harboring germline BRCA1/2 (gBRCA) mutations

Author

Milella, M., primary, Orsi, G., additional, Palloni, A., additional, Salvatore, L., additional, Procaccio, L., additional, Noventa, S., additional, Bozzarelli, S., additional, Garajova, I., additional, Vasile, E., additional, Giordano, G., additional, Macchini, M., additional, Cavaliere, A., additional, Gaule, M., additional, Lonardi, S., additional, Di Marco, M.C., additional, Tortora, G., additional, Sperduti, I., additional, and Reni, M., additional

Published
2022
Full Text
View/download PDF

36. ROS1 rearrangements are uncommon in biliary tract cancers

Author

Mazzoni F., Petreni P., Vasile E., Panebianco M., Casadei Gardini A., Negri F., Lunghi A., Pillozzi S., Vivaldi C., Gervasi E., Frassineti G. L., Messerini L., Jocolle G., Bisagni A., Antonuzzo L., Rossi G., Mazzoni, F., Petreni, P., Vasile, E., Panebianco, M., Casadei Gardini, A., Negri, F., Lunghi, A., Pillozzi, S., Vivaldi, C., Gervasi, E., Frassineti, G. L., Messerini, L., Jocolle, G., Bisagni, A., Antonuzzo, L., and Rossi, G.

Subjects
Molecular target, Fluorescence in situ hybridization, Biliary tract cancers, Biomarker, Immuno‑ histochemistry, ROS1 rearrangements, Articles
Abstract

Biliary tract cancers (BTCs) are a pool of diseases with poor prognosis and there is no orphan drug available. Currently, no molecular targets have been tested as druggable oncogenic drivers. C‑ros oncogene 1 (ROS1) rearrangements have been previously described in various tumors, including BTCs; however, data regarding their incidence and biological significance are controversial. Therefore, a retrospective multi‑ center study was performed to assess the incidence of ROS1 rearrangements in BTCs by means of immunohistochemistry and fluorescence in situ hybridization (FISH). The present study failed to demonstrate ROS1 expression in a multicenter series of 150 cases with BTCs and revealed that D4D6 was the most specific clone compared with other ROS1 primary antibodies, namely PA1‑30318 and EPMGHR2. Notably, nega‑ tive results obtained with D4D6 completely matched to data sorted out by FISH analysis, thus confirming a lack of ROS1 gene rearrangements in BTCs and false positive results when PA1‑30318 and EPMGHR2 clones were used. These results suggest that ROS1 rearrangements may not be targets for molecular therapy of BTCs with specific inhibitors.

Published
2020

38. 1479P Exploring second-line therapy outcome in pancreatic ductal adenocarcinoma (PDAC) patients with germlineBRCA1-2 pathogenic variants (gBRCA1-2pv)

Author

Orsi, G., primary, Milella, M., additional, Nappo, F., additional, Di Marco, M., additional, Niger, M., additional, Bozzarelli, S., additional, Rodriquenz, M.G., additional, Noventa, S., additional, Giordano, G., additional, Rapposelli, I.G., additional, Bernardini, I., additional, Vasile, E., additional, Macchini, M., additional, Peretti, U., additional, Valente, M.M., additional, Paratore, C., additional, Spallanzani, A., additional, Scartozzi, M., additional, Cascinu, S., additional, and Reni, M., additional

Published
2021
Full Text
View/download PDF

49. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib

Author

Hammel P., Kindler H. L., Reni M., Van Cutsem E., MacArulla T., Hall M. J., Park J. O., Hochhauser D., Arnold D., Oh D. -Y., Reinacher-Schick A., Tortora G., Algul H., O'Reilly E. M., McGuinness D., Cui K. Y., Joo S., Yoo H. K., Patel N., Golan T., Chantrill L., Goldstein D., Joubert W., Pavlakis N., Tognela A., Van Fraeyenhove F., Van Laethem J. -L., Peeters M., Dhani N., Kavan P., Lemay F., Adenis A., Artru P., Baba-Hamed N., Belletier C., Ben Abdelghani M., Blanc J. -F., Borg C., Coriat R., Deplanque G., Faroux R., Follana P., Guimbaud R., El Hajbi F., Hautefeuille V., Malka D., Metges J. -P., Tougeron D., Walter T., Ettrich T., Hacker U. T., Hennes E., Jacobasch L., Kanzler S., Pession U., Scholz C., Sinn M., Stein A., Strassburg C., Vogel A., Ben-Shahar M., Brenner R., Epelbaum R., Geva R., Gluzman A., Idelevich E., Kolin M., Semenisty V., Shai A., Stemmer S., Yarom N., Celio L., Conte P., Garufi C., Gianni L., Leonardi F., Maiello E., Di Marco M., Milella M., Pinto C., Santini D., Scartozzi M., Vaccaro V., Vasile E., Kim J. -W., Oh Park J., Wilmink H., Gallego R. A., Ogalla G. D., Velasco A. G., Cabanas E. G., Gomez Martin C., Ponce C. G., Saez B. L., Lopez R., Martin A. M., Pazo R., Pijaume C. P., Rodriguez J., Yaya-Tur R., Arora A., Anthoney D. A., Jeffrey Evans T. R., Harrison M., Palmer D., Sarker D., Starling N., Valle J., Wall L., Agajanian R., Bearden J., Bekaii-Saab T., Carter C., Cohen D., Distefano A., Dragovich T., Ejadi S., Ford J., Grabelsky S., Hall M., Hochster H., Hosein P., Javle M., Kindler H., Lacy J., Laheru D., Leong S., Lowery M., Marsh R., Noonan A., Oberstein P., Ocean A., O'Reilly E., Ryan D., Seery T., Subramaniam S., Van Echo D., Wang-Gillam A., Weekes C., Welch S., Hammel P., Kindler H.L., Reni M., Van Cutsem E., MacArulla T., Hall M.J., Park J.O., Hochhauser D., Arnold D., Oh D.-Y., Reinacher-Schick A., Tortora G., Algul H., O'Reilly E.M., McGuinness D., Cui K.Y., Joo S., Yoo H.K., Patel N., Golan T., Chantrill L., Goldstein D., Joubert W., Pavlakis N., Tognela A., Van Fraeyenhove F., Van Laethem J.-L., Peeters M., Dhani N., Kavan P., Lemay F., Adenis A., Artru P., Baba-Hamed N., Belletier C., Ben Abdelghani M., Blanc J.-F., Borg C., Coriat R., Deplanque G., Faroux R., Follana P., Guimbaud R., El Hajbi F., Hautefeuille V., Malka D., Metges J.-P., Tougeron D., Walter T., Ettrich T., Hacker U.T., Hennes E., Jacobasch L., Kanzler S., Pession U., Scholz C., Sinn M., Stein A., Strassburg C., Vogel A., Ben-Shahar M., Brenner R., Epelbaum R., Geva R., Gluzman A., Idelevich E., Kolin M., Semenisty V., Shai A., Stemmer S., Yarom N., Celio L., Conte P., Garufi C., Gianni L., Leonardi F., Maiello E., Di Marco M., Milella M., Pinto C., Santini D., Scartozzi M., Vaccaro V., Vasile E., Kim J.-W., Oh Park J., Wilmink H., Gallego R.A., Ogalla G.D., Velasco A.G., Cabanas E.G., Gomez Martin C., Ponce C.G., Saez B.L., Lopez R., Martin A.M., Pazo R., Pijaume C.P., Rodriguez J., Yaya-Tur R., Arora A., Anthoney D.A., Jeffrey Evans T.R., Harrison M., Palmer D., Sarker D., Starling N., Valle J., Wall L., Agajanian R., Bearden J., Bekaii-Saab T., Carter C., Cohen D., Distefano A., Dragovich T., Ejadi S., Ford J., Grabelsky S., Hall M., Hochster H., Hosein P., Javle M., Kindler H., Lacy J., Laheru D., Leong S., Lowery M., Marsh R., Noonan A., Oberstein P., Ocean A., O'Reilly E., Ryan D., Seery T., Subramaniam S., Van Echo D., Wang-Gillam A., Weekes C., Welch S., Institut Català de la Salut, [Hammel P] Department of Digestive Oncology, Hôpital Beaujon (AP-HP), Clichy, and University Paris VII, Paris, France. [Kindler HL] Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, USA. [Reni M] Department of Oncology, IRCCS Ospedale San Raffaele Scientific Institute, Milan, Italy. [Van Cutsem E] Division of Digestive Oncology, University Hospitals Gasthuisberg and KU Leuven, Leuven, Belgium. [Macarulla T] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology, Barcelona, Spain. [Hall MJ] Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA, Vall d'Hebron Barcelona Hospital Campus, CCA - Cancer Treatment and Quality of Life, and Oncology

Subjects
Male, 0301 basic medicine, Oncology, medicine.medical_treatment, BRCA, pancreatic cancer, Disease, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Piperazines, Germline, Medicaments antineoplàstics, chemistry.chemical_compound, 0302 clinical medicine, Quality of life, Neoplasm Metastasis, neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias pancreáticas [ENFERMEDADES], ambiente y salud pública::salud pública::medidas epidemiológicas::demografía::estado de salud::calidad de vida [ATENCIÓN DE SALUD], BRCA1 Protein, Neoplasms::Neoplastic Processes::Neoplasm Metastasis [DISEASES], Hematology, Middle Aged, Progression-Free Survival, humanities, 3. Good health, metastatic, health-related quality of life, 030220 oncology & carcinogenesis, Female, Adult, medicine.medical_specialty, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Poly(ADP-ribose) Polymerase Inhibitors, Placebo, olaparib, Olaparib, 03 medical and health sciences, Double-Blind Method, Metàstasi, Pancreatic cancer, Internal medicine, Gastrointestinal Tumors, medicine, Humans, Germ-Line Mutation, Aged, BRCA2 Protein, Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Pancreatic Neoplasms [DISEASES], Chemotherapy, Pàncrees - Càncer, business.industry, BRCA mutation, Original Articles, medicine.disease, Pancreatic Neoplasms, Environment and Public Health::Public Health::Epidemiologic Measurements::Demography::Health Status::Quality of Life [HEALTH CARE], 030104 developmental biology, chemistry, neoplasias::procesos neoplásicos::metástasis neoplásica [ENFERMEDADES], Quality of Life, Phthalazines, Neoplasm Recurrence, Local, business
Abstract

Qualitat de vida relacionada amb la salut; Olaparib; Càncer de pàncrees Calidad de vida relacionada con la salud; Olaparib, Cáncer de páncreas Health-related quality of life; Olaparib; Pancreatic cancer Background Patients with metastatic pancreatic cancer often have a detriment in health-related quality of life (HRQoL). In the randomized, double-blind, phase III POLO trial progression-free survival was significantly longer with maintenance olaparib, a poly(ADP-ribose) polymerase inhibitor, than placebo in patients with a germline BRCA1 and/or BRCA2 mutation (gBRCAm) and metastatic pancreatic cancer whose disease had not progressed during first-line platinum-based chemotherapy. The prespecified HRQoL evaluation is reported here. Patients and methods Patients were randomized to receive maintenance olaparib (300 mg b.i.d.; tablets) or placebo. HRQoL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item module at baseline, every 4 weeks until disease progression, at discontinuation, and 30 days after last dose. Scores ranged from 0 to 100; a ≥10-point change or difference between arms was considered clinically meaningful. Adjusted mean change from baseline was analysed using a mixed model for repeated measures. Time to sustained clinically meaningful deterioration (TSCMD) was analysed using a log-rank test. Results Of 154 randomized patients, 89 of 92 olaparib-arm and 58 of 62 placebo-arm patients were included in HRQoL analyses. The adjusted mean change in Global Health Status (GHS) score from baseline was

Published
2019

50. Epitaxial highly ordered Sb:SnO2 nanowires grown by the vapor liquid solid mechanism on m-, r- and a-Al2O3

Author

Zervos, Matthew, Lathiotakis, N., Kelaidis, N., Othonos, Andreas, Tanasa, E., Vasile, E., Zervos, Matthew [0000-0002-6321-233X], Othonos, Andreas [0000-0003-0016-9116], Vasile, E. [0000-0002-5868-1932], and Lathiotakis, N. [0000-0002-5589-7930]

Subjects
Photoluminescence, Materials science, Doping, General Engineering, Analytical chemistry, Nanowire, Bioengineering, General Chemistry, Crystal structure, Epitaxy, Atomic and Molecular Physics, and Optics, Tetragonal crystal system, Rutile, Impurity, General Materials Science
Abstract

Epitaxial, highly ordered Sb:SnO2 nanowires were grown by the vapor–liquid–solid mechanism on m-, r- and a-Al2O3 between 700 °C and 1000 °C using metallic Sn and Sb with a mass ratio of Sn/Sb = 0.15 ± 0.05 under a flow of Ar and O2 at 1 ± 0.5 mbar. We find that effective doping and ordering can only be achieved inside this narrow window of growth conditions. The Sb:SnO2 nanowires have the tetragonal rutile crystal structure and are inclined along two mutually perpendicular directions forming a rectangular mesh on m-Al2O3 while those on r-Al2O3 are oriented in one direction. The growth directions do not change by varying the growth temperature between 700 °C and 1000 °C but the carrier density decreased from 8 × 1019 cm−3 to 4 × 1017 cm−3 due to the re-evaporation and limited incorporation of Sb donor impurities in SnO2. The Sb:SnO2 nanowires on r-Al2O3 had an optical transmission of 80% above 800 nm and displayed very long photoluminescence lifetimes of 0.2 ms at 300 K. We show that selective area location growth of highly ordered Sb:SnO2 nanowires is possible by patterning the catalyst which is important for the realization of novel nanoscale devices such as nanowire solar cells. 1 5 1980 1990

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results